CORPORATE - mdxhealth.com...Corporate Presentation I U.S. Annual Market Opportunity 7 Prostate Cancer is the Most Common Cancer in American Men Estimated 3M Men eligible for à $1.5B

CORPORATE PRESENTATION

October 2020

Corporate Presentation I©2020. All rights reserved

This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the

anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on variousassumptions & assessments of known & unknown risks, uncertainties & other factors, which were deemed reasonable when made but

may or may not prove to be correct. Actual events are difficult to predict & may depend upon factors that are beyond the Company’scontrol. Therefore, actual results, the financial condition, performance or achievements of MDxHealth, or industry results, may turn out tobe materially different from any future results, performance or achievements expressed or implied by such statements & estimates. Given

these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements & estimates.MDxHealth disclaims any obligation to update any such forward-looking statement or estimates to reflect any change in the Company’s

expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement or estimate is based,except to the extent required by Belgian law.

Forward Looking Statement

2

Any opinions, estimates or forecasts made by analysts are theirs alone and do not represent opinions, forecasts or predictions ofMDxHealth or its management. Requests for copies of analyst reports should be directed at the respective analyst and institution.

Analyst Coverage

Providing clinically actionable information to improve patient outcomes

Improving patient care while reducing medical costs

Providing a value-based experience for patients, clinicians and providers

Delivering life changing genomic technologies to improve the early detection of prostate cancer

Corporate Presentation I

Ticker: MDXH.BR

© 2020. All rights reserved 3

©2020. All rights reservedCorporate Presentation I

Experienced Leadership TeamProven track record of success

John BellanoChief Commercial Officer

Michael K. McGarrityChief Executive Officer

Joseph SolleeExecutive Vice President

Corp. Dev. & General Counsel

Ron KalfusChief Financial Officer

Miriam ReyesExecutive Vice President

Laboratory Operations

4


Two clinically validated, commercially established, revenue generating diagnostic tests for prostate cancer

Address unmet need to reduce diagnostic uncertainty, overdiagnosis and healthcare costs by informing better treatment decisions in prostate cancer

Scalable commercial, reimbursement and medical infrastructure, which will drive expanded market adoption

Novel tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies to assist physicians with the diagnosis of urologic cancersCurrent tests have Intellectual Property protection with comprehensive portfolio of both issued and pending patents

Investment Highlights

5

Experienced management team comprised of industry leaders in diagnostics and life sciences, with proven track record in commercial and operating execution

Financial leverage to drive growth into current customer base and as well as expanded applications in the prostate cancer clinical utility pathway


Current Challenges with Diagnosing Prostate Cancer in the U.S.2020 ACS Surveillance Research

6

3 million elevated PSA results annually(1-2)

of biopsies do not reveal cancer and may lead to increased complications and hospitalization(3-6)

of negative biopsies are false negatives leading to invasive and costly interventions(7,8)

500,000 men undergo biopsies annually

191,930

116,30078,300 62,100 60,190

PROSTATE LUNG & BRONCHUS

COLON & RECTUM

URINARY BLADDER

MELANOMA OF THE SKIN

#1 Most Common Cancer in U.S. Men

72,500

33,330 28,630 24,640 20,020

LUNG & BRONCHUS

PROSTATE COLON & RECTUM

PANCREAS LIVER & BILE DUCT

#2 Deadliest Cancer in U.S. Men

60%

30%


U.S. Annual Market Opportunity

7

Prostate Cancer is the Most Common Cancer in American Men

Estimated 3MMen eligible for à $1.5B Market Opportunity

Who needs a biopsy?

Who needs arepeat biopsy?

>10% of tests are elevated

~60% of biopsies are negative

25MPSA testsperformed

500KProstate biopsies

performed

200KNew prostate cancer cases

3MLiving with prostate

cancer

33,350Estimated Deaths

Who needs treatment?

Estimated 300K

Men eligible for à $500M Market Opportunity


MDxHealth’s Prostate Cancer Menu

Positive

Negative

No Cancer

Cancer

Positive

Negative

Improving the decision forinitial prostate biopsy

Improving the decision forrepeat prostate biopsy

Routine Screening

Biopsy /Imaging

8

Clinical Pathway for Diagnosing Aggressive Prostate Cancer

Biopsy /Imaging


• Non-invasive “Rule-out”: Help improve the detection of clinically significant cancer by avoiding approximately half of excess prostate biopsies.

• 95% Negative Predictive Value3 for clinically significant prostate cancer

• Included in the NCCN & EAU guidelines4

• Cost effectiveness study demonstrated SelectMDx potential cost savings of >$500 million to U.S. health care system5 and >14,000 QALY gained5

Improved Patient Selection Prior to Prostate Biopsy

9

The most highly predictive test to help identify men at low risk for aggressive prostate cancer

of initial biopsies do not reveal prostate

cancer(1,2)

~ 60%

Abnormal PSA/DREBinary Actionable Results for

patient and HCP

Positive

Negative RoutinelyMonitor

Biopsy

95% NPV

At risk for aggressive cancer?


: Robust Clinical Evidence12 published studies on genes and technology (> 3,500 patients)

10

Pivotal Clinical Studies

Analytical Validation Hessels et al., Translational Medicine Communications 2017

>$500M In Savings To Health Care System Govers et al., Journal of Urology 2018

Clinically Validated For a 95% NPV Haese et al., Journal of Urology 2019

Significantly Impacts Prostate Biopsy Decision Making Shore et al., Urology Practice 2019

Clinical Utility Clinical Validity Analytical Validity Health Economics


• Non-invasive tissue biopsy test

• 96% Negative Predictive Value3 for clinically significant prostate cancer

• >55 published studies on genes and technology

• Included in EAU and NCCN guidelines4,5

• Covered by Medicare & commercial payers

• Significant potential savings to the health system

11

The only epigenetic test to identify men at risk for aggressive prostate cancer12-core needle biopsy could miss the mark

Positive

Negative Avoid Rebiopsy /MRI

RebiopsyMRI

of men with a negative biopsy result actually have

prostate cancer (1,2)

~30%

Negative biopsy 96% NPV3

Cancer

Biopsy CoreNeedles

Prostate

Biopsy Core

Prostate

Cancer

Urethra

Field Effect

Positive


: Robust Clinical EvidenceOver 55 published studies on genes and technology (> 5,500 patients)

12

Pivotal Clinical Studies

Analytical ValidationVan Neste et al., BMC Urology 2013

$500K In Savings To Health Care SystemAubry et al., American Health Drug and Benefits 2013

Validation of Clinical Utility/Actionability Wojno., et al 2014

Validation of High NPV Partin et al., Journal of Urology 2014.

Meta Analysis Validating High NPV Partin et al., Trans. of the Am. Clin. and Clim. Assoc 2016.

Risk Score Development NPV 96% CS Pca Van Neste et al. The Prostate 2016

Validated In African American Men Waterhouse et al., Urology 2016

Clinical Utility Clinical Validity Analytical Validity Health Economics


13

2012

PSA screening reduced/eliminated due

to US Preventive Services Task Force

downgrading

ConfirmMDx is included in the NCCN

Early Detection of Prostate Cancer

Guidelines

2016 2018

PSA testing resumes due to US Preventive Services Task Force

upgrading

2018

MDxHealth tests included in European Association of Urology

Prostate Cancer Guidelines

2020

SelectMDx is included in the NCCN

Early Detection of Prostate Cancer

Guidelines

NCCN NCCN

Clinical Guideline Inclusion


Expanding R&D Into the Prostate Cancer Diagnostic Pathway

14

SCREENING ACTIVE SURVEILLANCE (AS) InterventionDIAGNOSISPATIENT SELECTION

Active Surveillance AS monitoring

Prostate Cancer PSA Screening Test

InitialBiopsy

Low-Grade Prostate Cancer

High-grade Prostate Cancer Intervention

Biopsy decision

AS-MDx Monitor-MDx Intervention

Biopsy Negative Biopsy/Imaging


Low-grade prostate cancer

AS-MDx

AS-MDx

Not all men diagnosed with localized prostate cancer may benefit from immediate intervention. These tumors can be slow growing and non-life threatening

AS-MDx can help identify patients at lower risk of disease that may benefit from active surveillance, versus those at higher risk who should consider immediate intervention

AS-MDx aids in the disposition of patients at higher risk for disease progression whom may benefit from immediate intervention

Positive Intervention

Negative Active Surveillance

AS-MDx: Diagnostic Patient Disposition for Active Surveillance

15

134KEst. Market size (Men Annually)


Under Active Surveillance

(Low-grade cancer)

Monitor-MDx

Monitor-MDx

Patients under active surveillance are currently monitored by invasive and costly prostate biopsy procedures

• Monitor-MDx provides non-invasive risk stratification for patients under active surveillance for low grade prostate cancer

• Monitor-MDx can help reduce the risk of patients not returning for their annual assessment due to complacency or poor compliance

Positive Intervention

Negative Continued Active Surveillance

Monitor-MDx: Validates Continued Monitoring Under Active Surveillance

Monitor-MDx can help identify patients under active surveillance that have an increased risk of disease progression

16

1.5MEst. Market size (Men Annually)


Proven Fundamental Foundation Driving Value Creation

Strong Commercial Focus and Presence

Leveraging direct sales force in U.S.

Driving utilization through existing U.S. customer base

Employ OUS distribution partners for worldwide expansion

Proven Reimbursement Strategy

ConfirmMDx covered by Medicare and commercial payers

Recent inclusion in NCCN Guidelines will drive coverage for SelectMDx

Executed necessary health economic and clinical utility studies for broad insurance coverage

Robust and Reliable Technology

Proprietary IP portfolio capable of advancing our diagnostic pathway in prostate cancer

World-class laboratory operations: CAP and CLIA accredited / ISO 13485:2016 certified / NYSDOH approved

Extensive library of biomarkers and peer-reviewed publications to apply into prostate and additional disease states

17


MDxHealth Adoption and Reorder Rates Accelerating

• Considerable value in the current MDxHealth menu and customer base will drive significant revenue growth, as adoption progresses up the S-curve

• By driving adoption through our high-quality physician base with the current test offering, MDxHealth anticipates continued strong reordering from this segment as additional coverage is initiated

18

Adop

tion

rate

>200,000 tests ordered

Diagnostic S-curve adoption model

Time


0

20

40

60

80

100

120

2013 2014 2015 2016 2017 2018 2019 1H20

ConfirmMDx Contracts SelectMDx Contracts

ü 2016 NCCN Guidelines inclusionü 96 payer contracts – 1H20

ü 2020 NCCN Guidelines inclusionü 33 payer contracts – 1H20

MDxHealth Guideline Inclusion and Managed Care Contracts

Payer Adoption Summary

ConfirmMDx LCD(Medicare coverage)

19

ConfirmMDx and SelectMDx in EAU

ConfirmMDxin NCCN

SelectMDxin NCCN

Launch

Launch(2H14)

(1H16)

(1H18)

(2H20)


Robust and Reliable Technology

20

• MDxHealth continues to be at the forefront of researching and understanding the link between cancer and methylation,and how this link can be translated into meaningful molecular diagnostic tests.

• MDxHealth utilizes proprietary molecular technologies to advance cancer diagnosis and treatment. Individual DNAbiomarkers in the human body can become modified in the presence of cancer. MDxHealth’s solutions/technologiesidentify these modifications at the genetic level, improving the diagnosis and associated treatment of prostate cancer.

• MDxHealth owns or holds exclusive rights to a range of issued and pending patents in multiple countries covering thegenetic, epigenetic (methylation) and other molecular biomarkers and platform technologies.

– Comprehensive Intellectual Property portfolio as well as significant value associated with know-how and tradesecrets

• MDxHealth laboratories located in Irvine, CA and Nijmegen, The Netherlands


U.S. Headquarters & Laboratory15279 Alton Parkway, Ste 100

Irvine, CA 92618United States

Global HeadquartersCAP Business Center

Rue d’Abhooz, 314040 Herstal, Belgium

R&D & LaboratoryNovio Tech Campus Transistorweg 5

6534 AT NijmegenThe Netherlands

Thank You

General [email protected]

Investor Relations Contact

LifeSci Advisors, LLC (IR & PR)

US +1 949 271 9223

[email protected]

Global Operations

21


ConfirmMDx

SelectMDx &ConfirmMDx

SelectMDx

Presentation References

22

SUMMARY REFERENCE CITATIONSSlide 6 – Current challenges with diagnosing prostate cancer in U.S.1. NIH 8/20/2019 Website: https://seer.cancer.gov/statfacts/html/common.html. 2. MDxHealth management estimates3. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–134. 4. Bhindi B, Mamdani M, Kulkarni GS, et al. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol.

2015;193:1519–1524. 5. Loeb et al. European Urology 2013. 6. Loeb et al. Journal of Urology 2011. 7. Pinsky PF et al:. BJU International 99, no. 4 (April 2007): 775–779. 8. Resnick M et al:, Urology 2011. Mar 77: 548–552

Slide 9 – The most highly predictive test to help identify men at low risk for aggressive prostate cancer

1. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–134. 2. Bhindi B, Mamdani M, Kulkarni GS, et al. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol.

2015;193:1519–1524. 3. Haese, A, et al. (2019) Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy. J Uro. doi:

10.1097/JU.0000000000000293; 4. 2018 EAU,ESTRO,SIOG Guidelines on Prostate Cancer; 5. Govers TM, et al. (2018) Cost-Effectiveness of Urinary Biomarkernel in Prostate Cancer Risk Assessment. J Urol. doi: 10.1016/j.juro.2018.07.034A

Slide 11 – The only epigenetic test to identify men at risk for aggressive prostate cancer1. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–134. 2. Bhindi B, Mamdani M, Kulkarni GS, et al. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol.

2015;193:1519–1524. 3. Haese, A, et al. (2019) Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy. J Uro. doi:

10.1097/JU.0000000000000293; 4. 2018 EAU,ESTRO,SIOG Guidelines on Prostate Cancer; 5. Govers TM, et al. (2018) Cost-Effectiveness of Urinary Biomarkernel in Prostate Cancer Risk Assessment. J Urol. doi: 10.1016/j.juro.2018.07.034A
https://seer.cancer.gov/statfacts/html/common.html

CORPORATE - mdxhealth.com...Corporate Presentation I U.S. Annual Market Opportunity 7 Prostate Cancer is the Most Common Cancer in American Men Estimated 3M Men eligible for à $1.5B

Documents